The surprising ability of thalidomide and its analogs to treat various hematologic malignancies is through the loss of two transcription factors.
PERSPECTIVES order of magnitude improvement over the previous bound measured in YbF ( 3) .
An alternative approach to neutral beams is to use trapped molecular ions. For an ion held in a radio-frequency trap, a static electric fi eld of suffi cient strength to polarize the molecule will also push it out of the trap. The proposed solution to the problem was applying a strong rotating fi eld ( 4) . In the frame of that fi eld, one gains the benefi ts of both holding trapped ions for a long time and polarization of the molecule (see the fi gure).
Loh et al. use the rotating fi eld method to limit the electron electric dipole moment to be less than 1.5 × 10 −25 e⋅cm. This initial experiment is three orders of magnitude above the ThO result of Baron et al. The experiment of Loh et al. shows that precision measurements can be performed with molecular ions, and future experiments will be competitive with the neutral molecule and atom measurements.
Of course, more exciting than limiting the electron electric dipole moment would be to measure it. Why does theoretical physics tell us to expect it, and what do we expect the magnitude to be? These are both challenging questions to explain simply. An electric dipole moment requires an interaction that violates both parity and time symmetry. Everyday laws of physics are invariant if we relabel forward and backward in space and time. However, the laws that govern subatomic particles are not. They satisfy a combined symmetry of charge conjugation, parity, and time.
The Standard Model of particle physics allows for a violation of time and parity symmetry, and from the known interactions we can estimate that the electron electric dipole moment will be smaller than 10 −38 e⋅cm ( 5) . Extensions to the Standard Model, for example, supersymmetric or left-right symmetric models, can produce electron electric dipole moments near the current limits of detection. As a result, tabletop experiments are beginning to limit which theoretical models are compatible with the observed world.
Normally, when considering questions about particle physics, one thinks of large particle accelerator experiments. The excitement of the discovery of the Higgs boson at the Large Hadron Collider (LHC) ( 6, 7) and the award of this year's Nobel prize for its prediction are testaments to this method of inquiry. A challenge for the tabletop experiments is that at present the results at the LHC are consistent with the Standard Model. The lack of detection of other new particles also limits possible theoretical models of our world and, as a result, the value of the electron electric dipole moment. It is unclear at the moment whether investigation at high precision or investigation at high energy will be fi rst to reveal additional physics beyond the Standard Model.
T he 55-year history of the drug thalidomide is Shakespearean in scope, awash in unintended consequences, tragedy, resilience, driven characters, and redemption. Indeed, the most notorious pharmaceutical of modern times comes replete with images of devastating birth defects still fi rmly embedded in the public consciousness. Less well known has been the resurgence in its use as a therapy to treat hematologic malignancy. On pages 305 and 301 of this issue, Lu et al.
( 1) and Krönke et al. ( 2) , respectively, report that thalidomide and derivative compounds have a toxic effect on multiple myeloma by causing the degradation of two transcription factors, Ikaros and Aiolos. This loss halts myeloma growth while simultaneously altering immune cell function.
In an archetypal example of drug repositioning, reports emerged 15 years ago that thalidomide could be profoundly effective in patients with multiple myeloma ( 3), a tumor of antibody-producing plasma cells in the bone marrow. The malignancy is characterized by anemia, bone fractures, kidney failure, and recurrent infection. Subsequently, the thalidomide analogs lenalidomide and pomalidomide (collectively called immune modulating drugs or IMiDs) were shown to be even more potent in treating multiple myeloma, and today these small molecules form a highly effective backbone of therapy for this increasingly treatable cancer and for other hematologic malignancies ( 4) .
Many studies over the years have sought to explain the mechanism of teratogenicity of thalidomide. Thalidomide, lenalidomide, and pomalidomide were found to have wide-ranging and seemingly disparate cellular actions, including induction of oxidative stress and inhibition of angiogenesis, as well as multiple effects on the immune system-enhanced production of the cytokine interleukin-2 (IL-2) (which spurs T cell production), inhibition of the cytokine tumor necrosis factor (TNF), and the stimulation of natural killer cells ( 5) . The property of antiangiogenesis inspired the suggestion that thalidomide might be useful as a lastgasp attempt to control drug-resistant multiple myeloma. A remarkable success story in controlling this cancer with thalidomide soon followed ( 3). Unfortunately, it did not take long to show that although antiangiogenesis may be a consequence of thalidomide therapy, it was not the mechanism of action that explained its clinical effect.
The seminal breakthrough emerged in 2010 when thalidomide was found to bind to the protein cereblon ( 6) . Cereblon forms an E3 ubiquitin ligase complex with the proteins damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (Roc1). This complex tags specifi c proteins with ubiquitin, thereby targeting them for proteolysis. The drug-protein interaction www.sciencemag.org SCIENCE VOL 343 17 JANUARY 2014 PERSPECTIVES disrupts the activity of the E3 ubiquitin ligase complex, which underpins the cytotoxic and immune-modulating effects of IMiDs. Some of these effects were reversible by overexpressing the downstream proteins whose expression was reduced following IMiD treatment, such as the transcription factors interferon regulatory factor 4 (IRF4) and Myc (7) (8) (9) ( 11, 12) . Aiolos is required for normal plasma cell development in mice ( 13) . The toxic effects on multiple myeloma cells resulting from the loss of these two transcription factors are reversed by deletion of critical cereblon-binding regions of Ikaros prior to drug treatment. Under normal conditions, Ikaros suppresses expression of the gene encoding IL-2 in T cells but conversely stimulates expression of IRF4 (a transcription factor that responds to infection). Thus, a decrease in Ikaros explains the perplexing question of how one drug can both activate the immune system (a boost in IL-2 production by T cells stimulates immune responses) and degrade B cell function (as the result of reduced IRF4 expression) simultaneously.
Analysis of the cereblon-Ikaros/Aiolos-IRF4/Myc signaling pathway now opens doors to developing of more precise and effective therapeutics and biomarkers for drug response while raising some more issues for biologists and clinicians. For example, how can Ikaros depletion simultaneously be an effective anticancer target but also act as a tumor suppressor underpinning the development of acute lymphoblastic leukemia, an early B cell malignancy ( 14) ? Presumably, different Ikaros isoforms function as regulators of gene expression in different cellular contexts. A logical progression might be that deletion of Ikaros by the IMiDs, under the wrong circumstances, could simultaneously kill multiple myeloma cells but promote pre-B cell leukemogenesis. Indeed, clinical experience demonstrates a slightly higher risk of leukemias and B cell malignancies in patients treated with immune modulatory drugs, albeit only after exposure to a second genotoxic DNA-damaging agent, such as Melphalan, a commonly used multiple myeloma treatment ( 15) . There are other clinical dilemmas that remain unexplained, such as why only one-third of relapsed patients respond to a single-agent immune modulatory drug and why patients lose cereblon or fi nd alternative pathways to become resistant to these drugs.
Another perplexing clinical dilemma is that the action of IMiD drugs seems to absolutely require effective proteasomal degradation of Ikaros and Aiolos -a fi nding that fl ies in the face of clinical experience, which seems to support that combining an immune modulator with a proteasome inhibitor as a highly effective strategy for treating multiple myeloma ( 4) . Evidently, the scientific saga of thalidomide and its analogs is a story still not fully told.
It is tempting to update the mythic tale of the Greek god Ikaros flying too close to the Sun, only to have his waxed wings melt, to the genomic-era equivalent as the namesake Ikaros transcription factor comes too close to its molecular sun-namely, cereblon that is bound to an immune modulatory drug, with its inevitable degradation (see the fi gure). A fi nal but speculative conclusion of the studies by Lu et al. and Krönke et al. is that small molecules that enhance the ubiquitination and degradation of specifi c target proteins may represent a new class of therapeutics for manipulating proteins that were previously viewed as undruggable.
